Two separate randomized trials of Johnson & Johnson’s miniaturized Impella heart pumps failed to illustrate the devices’ benefits, spanning specific cases in patients with blockages in their coronary ... NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ... clickondetroit.com: Heart patients, doctors reunite to celebrate recoveries with ‘Impella’ device in Grosse Pointe Shores Heart patients, doctors reunite to celebrate recoveries with ‘Impella’ device in Grosse Pointe Shores MedTech Dive: J&J’s Impella heart pump shows no patient benefit in 2 trials Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat heart attack patients who don’t have cardiogenic shock.

Context Explanation

MedPage Today on MSN: Impella flops for acute coronary syndrome patients not in shock Johnson & Johnson (NYSE:JNJ) reported results from the randomized STEMI DTU trial of its Impella CP device at ACC 2026. The study assessed use of Impella CP before coronary intervention in heart ... A new life-saving technology was used during a heartfelt reunion thanks to the world’s smallest heart pump, Impella, giving patients a second chance at life ...